{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-158772","form_type":"8-K","ticker":null,"cik":"0001654151","company_name":"Deciphera Pharmaceuticals, Inc.","filed_at":"2024-06-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.445008+00:00","generated_at":"2026-06-01T05:04:39.608684+00:00","sec_items":["1.02","2.01","3.01","3.03","5.01","5.03","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Ono completes $2.4B acquisition of Deciphera; shares converted at $25.60 each","bullets":["88.3% of shares tendered; all conditions satisfied; merger effective June 11, 2024.","Each share converted to $25.60 cash; total consideration approx. $2.4 billion.","Deciphera becomes wholly owned subsidiary of Ono; board replaced by Toichi Takino and Masayuki Tanigawa.","Nasdaq listing suspended; Form 15 to be filed to terminate SEC reporting obligations.","2024 Annual Meeting cancelled due to closing of the merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-158772","json":"https://secwatch.observer/filing/0001193125-24-158772.json","markdown":"https://secwatch.observer/filing/0001193125-24-158772.md","text":"https://secwatch.observer/filing/0001193125-24-158772.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/d824393d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T05:04:39.608684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b1fe84986","claim":"Toichi Takino was appointed as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"12df2e873e","claim":"Dennis L. Walsh resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"34680158d2","claim":"James A. Bristol resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"358c25e44b","claim":"Ron Squarer resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"4021c2d4a1","claim":"Frank S. Friedman resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"808e40807e","claim":"Patricia L. Allen resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a0927e95d0","claim":"Susan L. Kelley resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"bb4d148f1c","claim":"Edward J. Benz, Jr. resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cda5ba0b85","claim":"Masayuki Tanigawa was appointed as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"dc48c31133","claim":"John R. Martin resigned as Director at Deciphera Pharmaceuticals, Inc..","evidence_excerpt":"Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ddacb510ff8387b8b94f57a133fb0242635514fe","claim":"Deciphera Pharmaceuticals, Inc. underwent a change of control involving Ono Pharmaceutical Co., Ltd. for $25.60 per share in cash (closed 2024-06-11).","evidence_excerpt":"May 13, 2024 to acquire all of the issued and outstanding shares of common stock, par value $0.01 per share, of the Company (“ Company Common Stock ”), at a price per share of $25.60, net to the seller in cash, without interest and subject to any withholding of taxes required by applicable law. The Offer and related withdrawal rights expired at one minute","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Ono Pharmaceutical Co., Ltd."},{"label":"Consideration","value":"$25.60 per share in cash"},{"label":"Closing","value":"2024-06-11"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}